FSD Pharma Inc. - Class B Subordinate Voting Shares (HUGE)

TORONTO, ON / ACCESSWIRE / August 23, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is planning to consolidate its issued and outstanding class A multiple voting shares and class B subordinate voting shares. The company also has announced a planned name change to Quantum BioPharma Ltd, with a new trading symbol of QNTM. The consolidation, which is part of the company’s efforts to regain compliance with NASDAQ’s minimum bid price, and name change are subject to approval by the NASDAQ exchange; if approved, the changes will be effective Aug. 15, 2024. These actions have all been approved by company shareholders at the annual general and special meeting of shareholders held on July 22, 2024.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is providing a status report on its investment in Celly Nutrition Corp. A privately held Canadian company, Celly Nu is launching an innovative beverage product designed to assist in expediting alcohol metabolism and faster recovery from alcohol consumption.

TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately held Canadian company launching an innovative beverage product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has been featured in a news report published by 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information. The report, which highlights functional beverage market developments, discusses FSD Pharma’s revolutionary rapid detoxification drink, unbuzzd(TM). The drink helps to rapidly restore mental alertness post-alcohol consumption.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is reporting on the results of its annual general and special meeting of shareholders; the in-person meeting was held on July 22, 2024, in Toronto, Ontario. According to the report, shareholders were represented in person or by proxy at the meeting. Shareholders elected seven directors for the company, with the directors serving until the next annual meeting or until a successor is elected or appointed; the elected directors include Anthony Durkacz, Zeeshan Saeed, Dr. Lakshmi P. Kotra, Adnan Bashir, Dr. Sanjiv Chopra, Michael (Zappy) Zapolin and Dr. Eric Hoskins. In addition, shareholders reappointed MNP LLP as the company’s auditor; approved a share consolidation resolution; approved a special resolution giving board members power to change the company’s name; passed a special resolution approving and ratifying the company’s articles of amendment; and passed an ordinary resolution authorizing the board to approve the issue of additional Class A multiple voting shares.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has filed an amended and restated material change report. According to the announcement, the report amended the disclosure in Section 5.1 of the original MCR. “The amended and restated material change report is being filed to provide additional disclosure with respect of the private placement offering of Class A multiple voting shares of the company that closed on Dec. 5, 2023,” stated the company in the press release. “The amended and restated MCR can be found on the company’s SEDAR+ profile.”

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced that it has partnered with Totaligent Inc. (OTC: TGNT) to assist the company in its efforts to enhance its market awareness. According to the announcement, FSD Pharma retained the services of Totaligent with an objective to “foster productive, continuing dialogues with shareholders and other market participants.” Totaligent brings more than two decades of experience in market-awareness campaigns to the table; the company also has a database of 32 million active investors, which it communicates with through email, SMS, social media, push notification, pay-per-click (“PPC”), search, and digital and print media. The announcement also noted that FSD Pharma issued 650,000 Class B subordinate voting shares in the capital of the corporation to arm’s length creditors; the shares were issued at $0.30 per Class B share and were issued to settle a debt of $195,000. “Totaligent has been engaged for a 30-day term, with either party having the right to terminate the engagement agreement upon providing five business-day notice,” the press release stated. “The contract total is $30,000 to be paid in cash. This contract was signed on June 28, 2024, and is expected to end on July 28, 2024, unless renewed by mutual consent. Totaligent and its principals are arm’s length parties to the company.”

TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that the United States District Court for the Eastern District of Pennsylvania ruled in favor of FSD Pharma and is granted its motion for entry of judgment against Dr. Raza Bokhari, the company’s former CEO. The decision awards FSD Pharma several awards, including $147,301.04 plus interest at a rate of 4% per annum from Nov. 9, 2022, until the date the judgment is satisfied; C$31,912.55 plus interest at a rate of 4% per annum from Nov. 9, 2022, until the date the judgment is satisfied; C$15,000 plus interest at a rate of 4% per annum from March 1, 2023, until the date the judgment is satisfied; and C$2,814,229.15 plus interest at a rate of 6% per annum from May 7, 2023, until the date the judgment is satisfied. The judgment results from action taken by Bokhari after FSD’s board of directors terminated him. “After years of litigation and an eight-day evidentiary hearing, the arbitrator ruled against Dr. Raza Bokhari and issued three awards against Dr. Raza Bokhari in favor of FSD, including an award for damages and awards for FSD’s fees and costs incurred in the arbitration,” stated the press release. “FSD will pursue all means possible to collect from Dr. Raza Bokhari, current chairman and CEO of Medicus Pharma Ltd.”

TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on June 27, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s motion for entry of judgment is granted and judgment is entered in favour of FSD Pharma and against Dr. Raza Bokhari as follows:

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received a key approval for its planned Lucid-21-302 trial. According to the announcement, the human ethics review committee (“HREC”) in Australia approved the trial, which is titled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A first-in-class, nonimmunomodulatory, neuroprotective compound, Lucid-21-302 offers a unique mechanism of action for the treatment of multiple sclerosis (“MS”). “After much hard work designing this MAD trial, we are thrilled that we have received HREC approval, and the trial can now commence,” said FSD Pharma vice president of scientific and clinical affairs Dr. Andrzej Chruscinski in the press release. “This marks an important step in the clinical development of Lucid-21-302 (Lucid-MS).”

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received a key approval for its planned Lucid-21-302 trial. According to the announcement, the human ethics review committee (“HREC”) in Australia approved the trial, which is titled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A first-in-class, nonimmunomodulatory, neuroprotective compound, Lucid-21-302 offers a unique mechanism of action for the treatment of multiple sclerosis (“MS”). “After much hard work designing this MAD trial, we are thrilled that we have received HREC approval, and the trial can now commence,” said FSD Pharma vice president of scientific and clinical affairs Dr. Andrzej Chruscinski in the press release. “This marks an important step in the clinical development of Lucid-21-302 (Lucid-MS).”

TORONTO, ON / ACCESSWIRE / June 27, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it has received approval by the human ethics review committee (HREC) in Australia for its trial entitled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants."

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an exclusive option agreement with the University of Southern California (“USC”). Signed June 11, 2024, the option agreement allows FSD Pharma to exclusively evaluate, for an initial term of six months, a novel dietary supplement technology for commercialization. At the end of this term, the company will have the option to either extend it for a further six months or to sign an exclusive license with USC for the technology. The company is evaluating this novel technology for the potential to further increase the effectiveness of certain ingredients currently present in unbuzzd(TM). Launching this summer, unbuzzd(TM) is a scientifically formulated blend of vitamins, minerals, and herbs. It is engineered to increase alcohol metabolism, enable faster recovery from alcohol consumption, and simultaneously improve mental alertness. “We are thrilled to sign the option agreement with USC. We are looking forward to evaluating this novel technology that has the potential to both further enhance the effectiveness of unbuzzd(TM) and increase our target market by enabling the development of new products,” said Zeeshan Saeed, Founder, CEO and Executive Co-Chairman at FSD Pharma, in the press release.

TORONTO, ON / ACCESSWIRE / June 13, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it entered into an exclusive option agreement with the University of Southern California (USC) to evaluate dietary supplement technology for commercialization. The option agreement, signed June 11, 2024, allows FSD Pharma to exclusively evaluate the novel technology for a 6-month term. At the end of this term, FSD Pharma will have the option to either extend it for an additional 6 months or to sign an exclusive license for the technology with USC. This novel technology is being evaluated for the potential to further increase the effectiveness of certain ingredients currently present in unbuzzd™. unbuzzd™ is a scientifically formulated blend of vitamins, minerals, and herbs engineered to expedite alcohol metabolism, facilitate faster recovery from alcohol consumption, and simultaneously enhance mental alertness to those individuals who consume it. FSD Pharma has partnered with Celly Nutrition, being led by beverage industry leaders Gerry David formerly CEO of Celsius Holdings, Inc. and John Duffy formerly of The Coca-Cola Company, to launch unbuzzd™ this summer.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received approval for its METAL-2 trial to be conducted in the United States. The approval came from the institutional review board (“IRB”). With the approval, FSD Pharma can now begin to plan execution of the clinical study and to recruit participants for the clinical trial. “We are excited that the METAL-2 trial has received IRB approval, allowing us to advance this clinical study in the United States,” said FSD Pharma vice president of clinical and scientific affairs Dr. Andrzej Chruscinski in the press release. “This marks an important milestone in our clinical research in the field of acute alcohol intoxication.”

TORONTO, ON / ACCESSWIRE / June 4, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today confirms that it has received institutional review board (IRB) approval for its METAL-2 trial in the USA. This IRB approval allows our team to begin recruiting clinical trial participants and to plan the execution of the clinical study.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, announced that the U.S. District Court for the Eastern District of Pennsylvania has confirmed its Petition to Confirm Arbitration Awards. The petition was entered against Dr. Raza Bokhari by a Canadian arbitrator in 2022. According to the announcement, the company will now move for entry of final judgment against Bokhari, who was terminated as FSD’s CEO in July 2021. Bokhari filed an arbitration challenging this termination, and after years of litigation and an eight-day evidentiary hearing, the arbitrator ruled against Bokhari and issued three awards in favor of FSD, including an award for damages and awards for FSD’s fees and costs incurred in the arbitration. “In its opinion granting FSD’s petition, the district court found that Bokhari did not offer any valid basis under the New York Convention for the court to deny enforcement of the arbitration awards against him,” stated the press release.

TORONTO, ON / ACCESSWIRE / May 31, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on May 29, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s Petition to Confirm Arbitration Awards entered against Dr. Raza Bokhari by a Canadian arbitrator in 2022. Pursuant to the Federal Rules of Civil Procedure, FSD will now move for entry of final judgment against Bokhari, as follows:

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd(TM) in healthy volunteers. The clinical trial protocol for the METAL-2 trial will be reviewed by the U.S. institutional review board. After receiving approval, the company will begin recruiting healthy volunteers for the study, which is designed to evaluate the ability of Unbuzzd to help alleviate the effects of acute alcohol intoxication. “We are thrilled that we have reached this important milestone and that we are now a step closer to assessing the safety and efficacy of Unbuzzd in a clinical trial,” said FSA Pharma vice president of clinical and scientific affairs Dr. Andrzej Chruscinski in the press release.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd(TM) in healthy volunteers. The clinical trial protocol for the METAL-2 trial will be reviewed by the U.S. institutional review board. After receiving approval, the company will begin recruiting healthy volunteers for the study, which is designed to evaluate the ability of Unbuzzd to help alleviate the effects of acute alcohol intoxication. “We are thrilled that we have reached this important milestone and that we are now a step closer to assessing the safety and efficacy of Unbuzzd in a clinical trial,” said FSA Pharma vice president of clinical and scientific affairs Dr. Andrzej Chruscinski in the press release.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an investor relations services agreement with IR Agency LLC. According to the announcement, the agreement, which was effective May 22, 2024, outlines IR Agency’s responsibilities to communicate information about FSD Pharma to the financial community. That information could include company profiles and media distribution as well as building a digital community. The agreement is for one month, with services beginning on May 28, 2024; the contract notes that FSD Pharma will pay a fee of C$335,699. IR Agency’s Rafael Pereira will be involved in providing the investor relations services to the FSD Pharma. IR Agency is committed to opening virtual doors for its clients, introducing them to life’s visionaries, innovators and pioneers — the kind of creative minds and deep-pocketed shareholders companies need to become an industry powerhouse.

TORONTO, ON / ACCESSWIRE / May 28, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today confirms the submission of a clinical trial protocol to assess the safety and efficacy of Unbuzzd™ in healthy volunteers (METAL-2 trial). The clinical trial protocol was submitted for review and approval by the institutional review board (IRB) in the USA. Recruitment of healthy volunteers to the trial will begin following approval by the IRB. In the METAL-2 trial, the ability of Unbuzzd™ to help alleviate the effects of acute alcohol intoxication will be studied in a crossover design.

TORONTO, ON / ACCESSWIRE / May 24, 2024 / FSD Pharma Inc. (NASDAQHUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it has entered into an investor relations services agreement with IR Agency LLC (the "Agency") effective May 22, 2024.